OpGen : Corporate Presentation

OpGen

Corporate Overview

November 1, 2022

OpGen, Inc.

Forward Looking Statements Disclaimer

This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1955. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond OpGen's control, and that may cause results to differ materially from expectations.

Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Company's operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward- looking statement, whether as a result of new information, future events or otherwise.

OpGen, Inc.

2

OpGen Overview

Striving to innovate molecular microbiology

Fast	Comprehensive	Smart	Easy

Rapid Pathogen	Broad Pathogen &	AI-Powered AMR	Sample-To-Answer
Detection For Life	Antimicrobial	Prediction &	Platforms
Threatening Infections	Resistance (AMR)	Bioinformatics
	Marker Coverage

OpGen, Inc.

3

OpGen's product portfolio

Next generation of diagnostic solutions

Together we improve patient care and

fight AMR through cutting edge molecular diagnostics

Syndromic	Broad AMR	AI-Powered
Bioinformatics
	Diagnostics	Detection
	& NGS Services

Our innovative solutions for infectious disease diagnostics comprise a suite of FDA-cleared rapid PCR-based panels as well as NGS-based services with AI-powered bioinformatics for molecular microbiology.

OpGen, Inc.

4

OpGen's strategic positioning and benefits

Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms

Premier AI-powered bioinformatics solutions for multi-drug resistance diagnostics

Global commercial channel capabilities & partners

Financial leverage, operational synergies, and positive growth-driven business outlook

OpGen, Inc.

5